Neurocrine Biosciences

NBIXNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$16.610 B

$163.41 +2.25%

Close of 7 Aug 2026

Revenue

$2.86B

#953 by revenue

Earnings

$478.6M

#631 by earnings

Shares outstanding

101,649,181

Latest filing cover page

P/E ratio

34.7

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances) — ranked by market cap

All 160 →

#6ModernaMRNA$23.6B
#7BioNTech SEBNTX$23.5B
#8Neurocrine BiosciencesNBIX$16.6B
#9ExelixisEXEL$13.4B
#10Halozyme TherapeuticsHALO$12.2B

Where these numbers come from

Share counts and financials for Neurocrine Biosciences are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.